New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:09 EDTRGLS, BIIBRegulus Therapeutics and Biogen enter into new collaboration agreement
Regulus Therapeutics (RGLS) announced that it has entered into a new collaboration agreement with Biogen (BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis, or MS, under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
News For RGLS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
12:26 EDTBIIBBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
April 30, 2015
16:54 EDTBIIBIsis Pharmaceuticals earns $10M milestone payment from Biogen
Subscribe for More Information
10:34 EDTBIIBPfizer 'mystery bidder' for Swedish Orphan Biovitrum, Reuters says
Subscribe for More Information
April 29, 2015
07:39 EDTBIIBBiogen, AbbVie say FDA accepts BLA for Zinbryta for treatment of MS
Biogen (BIIB) and AbbVie (ABBV) announced that the FDA has accepted for review the companiesí Biologics License Application requesting marketing approval of ZINBRYTA for relapsing forms of multiple sclerosis. Biogen and AbbVie announced in March 2015 that their Marketing Authorisation Application for ZINBRYTA was validated by the European Medicines Agency for review in the European Union. The BLA included results from two pivotal trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS.
April 28, 2015
11:43 EDTBIIBStocks with call strike movement; BIIB NFX
Subscribe for More Information
10:11 EDTBIIBPiper Jaffray biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 27, 2015
10:07 EDTBIIBForward Pharma receives decision to grant from EPO for DMF patent in Europe
Forward Pharma (FWP) announced that the company received a decision to grant from the European Patent Office regarding its patent application 14172398.1 which covers, among other things, the treatment of multiple sclerosis with 480 mg per day of dimethyl fumarate wherein the pH controlled release compositions have an enteric coat. The EPO projects that the application will issue under the patent number EP2801355 on May 20, 2015 with the publication of the mention of grant. We expect that the patent will provide protection until October 2025, assuming the company successfully defends the patent during any subsequent invalidation proceedings. This projected European patent is one of several elements of the company's intellectual property, which also includes three U.S. pending patent applications and two other European pending patent applications covering methods of treating multiple sclerosis with formulations that provide a 480 mg daily dose of DMF. Foward Pharma said "The EPO examiner allowed our 480 mg patent claims after considering third party observations both requesting the EPO to not grant the application as well as suspend its examination. Biogen (BIIB) markets Tecfidera, a product containing DMF as the active ingredient for the treatment of MS at a daily dose of 480 mg. Tecfidera was approved by the European Commission in January 2014. Worldwide sales of Tecfidera as reported by Biogen totalled over $3.2B in the last 12 months, including $614M of ex-US sales."
09:19 EDTBIIBBiogen shares should be bought on weakness, says BMO Capital
Subscribe for More Information
08:25 EDTBIIBBiogen coverage assumed with a Perform at Oppenheimer
Subscribe for More Information
08:15 EDTBIIBBiogen weakness creates buying opportunity, says RBC Capital
Subscribe for More Information
April 26, 2015
15:27 EDTRGLSRegulus reports 'impressive' data on RG-101 for the treatment of HCV
Subscribe for More Information
April 24, 2015
15:16 EDTBIIBBiogen sell off a buying opportunity, Barron's says
Biogen is down about 6% on the session after reporting Q1 results that missed expectations. The pullback represents a buying opportunity as the company's drug pipeline should fuel strong growth, Barron's says. Reference Link
09:28 EDTBIIBPiper says Biogen has 'long way to go' before being top pick again
Subscribe for More Information
09:20 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
07:40 EDTBIIBForward Pharma price target raised to $53 from $43 at Leerink
Subscribe for More Information
07:02 EDTBIIBBiogen reports Q1 Tecfidera revenue $825M
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year. Interferon revenues, including Avonex and Plegridy were $755M in Q1. Tysabri revenues were $463M. Net revenues relating to Rituxan and Gazyva were $331M. Elocate revenues were $54M, Alprolix revenues were $43M.
07:01 EDTBIIBBiogen reports Q1 adjusted EPS $3.82, consensus $3.91
Subscribe for More Information
April 23, 2015
15:07 EDTBIIBBiogen technical comments before earnings
Subscribe for More Information
15:01 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use